{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:06Z","timestamp":1780038126023,"version":"3.53.1"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The success of vaccines against varicella zoster virus (VZV) demonstrates the feasibility of high-level efficacy against clinical consequences of herpesvirus infection, but there is a need for new vaccines against others \u2013 in particular Epstein-Barr Virus (EBV), human cytomegalovirus (HCMV) and herpes simplex virus 1 and 2 (HSV). Herpesviruses use surface glycoproteins to trigger membrane fusion during cell invasion. Glycoprotein B (gB) is conserved across the family and acts as the fusogen. Vaccines based upon viral fusion proteins protect against many other viruses, and a gB-targeting HCMV vaccine achieved partial efficacy in clinical trials. This experience encourages development of improved gB-based antigens and formulations. There has recently been progress in stabilisation of the pre-fusion conformation of gB, which may be the more relevant structure with respect to immunological protection. Nonetheless gB-targeting vaccines have received less attention recently than vaccines against receptor-binding glycoproteins such as EBV gH\/gL and gp350, and HCMV pentamer. We therefore seek to review current knowledge regarding gB as a vaccine antigen: understanding of herpesvirus gB structure and function, within the context of the wider process of herpesvirus entry into host cells; insights relevant to vaccine development from\n                    <jats:italic>in vitro<\/jats:italic>\n                    studies of antibody-gB interactions and effects; and the results from previous\n                    <jats:italic>in vivo<\/jats:italic>\n                    studies using gB-based vaccines. We conclude by critically appraising the potential for gB antigens to contribute to future herpesvirus vaccines, as compared to alternative or complementary approaches.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1827628","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:07:53Z","timestamp":1780034873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Progress and prospects for herpesvirus vaccination using gB antigens"],"prefix":"10.3389","volume":"17","author":[{"given":"Solomon","family":"English","sequence":"first","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Khan-Qureshi","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford","place":["Oxford, United Kingdom"]},{"name":"Division of Structural Biology, Nuffield Department of Medicine, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Douglas","sequence":"additional","affiliation":[{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1517\/17460441.2014.922538","article-title":"Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach","volume":"9","author":"Hornig","year":"2014","journal-title":"Expert Opin Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.tim.2023.03.001","article-title":"Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents","volume":"31","author":"Zhong","year":"2023","journal-title":"Trends Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci136225","article-title":"Herpesvirus latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bsheal.2022.05.005","article-title":"Herpes B virus: History, zoonotic potential, and public health implications","volume":"4","author":"Hu","year":"2022","journal-title":"Biosaf Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8050685","article-title":"Where do we stand after decades of studying human cytomegalovirus","volume":"8","author":"Gugliesi","year":"2020","journal-title":"Microorganisms"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/v10110609","article-title":"Clinical features of varicella-zoster virus infection","volume":"10","author":"Kennedy","year":"2018","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.1982373","article-title":"Pathogenesis and virulence of herpes simplex virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Virulence"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/ITT.S176383","article-title":"Varicella zoster virus vaccines: an update","volume":"8","author":"Gabutti","year":"2019","journal-title":"ImmunoTargets Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.970545","article-title":"Alphaherpesvirus glycoprotein E: A review of its interactions with other proteins of the virus and its application in vaccinology","volume":"13","author":"Ning","year":"2022","journal-title":"Front Microbiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"B14","year":""},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2015.0012","article-title":"Herpes simplex virus: The interplay between HSV, host, and HIV-1","volume":"28","author":"Desai","year":"2015","journal-title":"Viral Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.044","article-title":"Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development","volume":"37","author":"Schiffer","year":"2019","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2012.011356","article-title":"Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention","volume":"23","author":"Thurman","year":"2012","journal-title":"Int J STD AIDS"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilised F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04356-8","article-title":"Broadly neutralising antibodies target a haemagglutinin anchor epitope","volume":"602","author":"Guthmiller","year":"2021","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v13040625","article-title":"Intervention strategies for seasonal and emerging respiratory viruses with drugs and vaccines targeting viral surface glycoproteins","volume":"13","author":"Tripp","year":"2021","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.03.004","article-title":"Vaccines to prevent genital herpes","volume":"220","author":"Egan","year":"2020","journal-title":"Trans Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867918","article-title":"Four decades of prophylactic EBV vaccine research: A systematic review and historical perspective","volume":"13","author":"Escalante","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41541-018-0074-4","article-title":"A new era in cytomegalovirus vaccinology: Considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection","volume":"3","author":"Nelson","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v13040625","article-title":"Vaccination against the Epstein\u2013Barr virus","volume":"77","author":"R\u00fchl","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-019-0591-5","article-title":"The promise of a prophylactic Epstein\u2013Barr virus vaccine","volume":"87","author":"Balfour","year":"2019","journal-title":"Pediatr Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020302","article-title":"Immune response to herpes simplex virus infection and vaccine development","volume":"8","author":"Ike","year":"2020","journal-title":"Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","volume":"34","author":"Johnston","year":"2016","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV vaccines","volume":"9","author":"van Zyl","year":"2019","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomised controlled trials","volume":"282","author":"Corey","year":"1999","journal-title":"J Am Med Assoc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1086\/514103","article-title":"Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial","volume":"176","author":"Straus","year":"1997","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ebiom.2019.11.005","article-title":"Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation","volume":"50","author":"Baraniak","year":"2019","journal-title":"EBioMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomised clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100787","article-title":"A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients","volume":"33","author":"Ljungman","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad593","article-title":"Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralisation and higher antibody-dependent cellular cytotoxicity responses than the gB\/MF59 vaccine","volume":"230","author":"Hu","year":"2024","journal-title":"J Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-94-007-0782-5_3","article-title":"Class III viral membrane fusion proteins","volume":"950","author":"Backovic","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00186-20","article-title":"Human cytomegalovirus glycoprotein B nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gB protein immunisation","volume":"94","author":"Nelson","year":"2020","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-018-0060-6","article-title":"Structural basis for membrane anchoring and fusion regulation of the herpes simplex virus fusogen Gb","volume":"25","author":"Cooper","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2210\/pdb9q9l\/pdb","article-title":"A nanobody specific to prefusion glycoprotein B neutralises HSV-1 and HSV-2","volume":"646","author":"Vollmer","year":"2025","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf3178","article-title":"Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-025-67969-x","article-title":"Structure and immunogenicity of an engineered soluble prefusion-stabilised EBV gB antigen","volume":"17","author":"McCool","year":"2026","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66099-8","article-title":"A broadly neutralising antibody confers cross-genus protection against alphaherpesviruses by inhibiting gB-mediated membrane fusion","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202507012","article-title":"Chimeric glycoprotein nanoparticles elicit robust neutralising antibodies against Epstein\u2013Barr virus","volume":"38","author":"Sun","year":"2025","journal-title":"Adv Mater"},{"key":"B47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10409230802058320","article-title":"Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme","volume":"43","author":"White","year":"2008","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7240","article-title":"Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nm1236","article-title":"Integrin \u03b1v\u03b23 is a coreceptor for human cytomegalovirus","volume":"11","author":"Wang","year":"2005","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.043","article-title":"PILR\u03b1 is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B","volume":"132","author":"Satoh","year":"2008","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00710-10","article-title":"The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry","volume":"84","author":"Feire","year":"2010","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/v7122957","article-title":"Herpesvirus gB: A finely tuned fusion machine","volume":"7","author":"Cooper","year":"2015","journal-title":"Viruses"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012846","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) gB dictates a low-pH endocytotic entry pathway as revealed by a dual-fluorescent virus system and a rhesus monkey rhadinovirus expressing KSHV gB","volume":"21","author":"Kaye","year":"2025","journal-title":"PloS Pathog"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02687-09","article-title":"Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH\/gL as a necessary step leading to cell fusion","volume":"84","author":"Atanasiu","year":"2010","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.virol.2010.12.006","article-title":"Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH\/gL","volume":"413","author":"Plate","year":"2011","journal-title":"Virology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02391-15","article-title":"Interplay between the herpes simplex virus 1 gB cytodomain and the gH cytotail during cell-cell fusion","volume":"89","author":"Rogalin","year":"2015","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/v14020296","article-title":"Well put together\u2014a guide to accessorising with the herpesvirus gH\/gL complexes","volume":"14","author":"Gonzalez-Del Pino","year":"2022","journal-title":"Viruses"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02039-22","article-title":"Herpes simplex virus 1 entry glycoproteins form complexes before and during membrane fusion","volume":"13","author":"Pataki","year":"2022","journal-title":"mBio"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005564","article-title":"Human cytomegalovirus gH\/gL forms a stable complex with the fusion protein gB in virions","volume":"12","author":"Britt","year":"2016","journal-title":"PloS Pathog"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007452","article-title":"Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate","volume":"14","author":"Rey","year":"2018","journal-title":"PloS Pathog"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010435","article-title":"A surface pocket in the cytoplasmic domain of the herpes simplex virus fusogen gB controls membrane fusion","volume":"18","author":"Pataki","year":"2022","journal-title":"PloS Pathog"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01905-25","article-title":"Mutational dissection of HCMV gB and gH cytoplasmic tails highlights conserved and divergent features of fusion regulation","volume":"16","author":"Lee","year":"2025","journal-title":"mBio"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2210\/pdb3fvc\/pdb","article-title":"Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B","volume":"106","author":"Backovic","year":"2009","journal-title":"PNAS"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms9176","article-title":"Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralising human antibody","volume":"6","author":"Chandramouli","year":"2015","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17911-0","article-title":"A glycoprotein B-neutralising antibody structure at 2.8\u2009\u00c5 uncovers a critical domain for herpesvirus fusion initiation","volume":"11","author":"Oliver","year":"2020","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.23.619923","article-title":"Computational design of prefusion-stabilised Herpesvirus gB trimers","author":"McCallum","year":"2024","journal-title":"bioRxiv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404250121","article-title":"Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilised in a prefusion-like conformation","volume":"121","author":"Sponholtz","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fvl-2017-0124","article-title":"Recent insights into the structural characterisation of herpes simplex virus fusion protein, gB","author":"Vennard","year":"2018","journal-title":"Future Virol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059863","article-title":"Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130\u2013131 complex during primary infection","volume":"8","author":"Lilleri","year":"2013","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralising antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein-Barr virus (EBV) gp350 correlate with neutralisation of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralisation assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01930-14","article-title":"Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans downloaded from","volume":"88","author":"Cairns","year":"2014","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00269-18","article-title":"Breadth and functionality of varicella-zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans","volume":"92","author":"Sullivan","year":"2018","journal-title":"J Virol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunised with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralising activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.053","article-title":"Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus","volume":"30","author":"Fu","year":"2012","journal-title":"Vaccine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralising antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040182","article-title":"MVA-vectored pentameric complex (PC) and gB vaccines improve pregnancy outcome after Guinea pig CMV challenge, but only gB vaccine reduces vertical transmission","volume":"7","author":"Contreras","year":"2019","journal-title":"Vaccines"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020179","article-title":"Immunisation with human cytomegalovirus core fusion machinery and accessory envelope proteins elicit strong synergistic neutralising activities","volume":"8","author":"Cui","year":"2020","journal-title":"Vaccines"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralising antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202371119","article-title":"Protective anti-gB neutralising antibodies targeting two vulnerable sites for EBV-cell membrane fusion","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008736","article-title":"Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralising HCMV at a post-attachment step","volume":"16","author":"Kalejta","year":"2020","journal-title":"PloS Pathog"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1128\/aac.04295-14","article-title":"A high-affinity native human antibody neutralises human cytomegalovirus infection of diverse cell types","volume":"59","author":"Kauvar","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralise human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1016\/j.immuni.2023.10.009","article-title":"Single-cell analysis of memory B cells from top neutralisers reveals multiple sites of vulnerability within HCMV trimer and pentamer","volume":"56","author":"Zehner","year":"2023","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.9.5290-5297.1992","article-title":"A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus","volume":"66","author":"Wagner","year":"1992","journal-title":"J Virol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02710-06","article-title":"Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions","volume":"81","author":"Bender","year":"2007","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-9-2375","article-title":"Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies","volume":"73","author":"Meyer","year":"1992","journal-title":"J Gen Virol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00821-3","article-title":"Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth","volume":"9","author":"Wang","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.2.703-710.1993","article-title":"Fine specificity of the human immune response to the major neutralisation epitopes expressed on cytomegalovirus gp58\/116 (gB), as determined with human monoclonal antibodies","volume":"67","author":"Ohlin","year":"1993","journal-title":"J Virol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02422-20","article-title":"Potent bispecific neutralising antibody targeting glycoprotein B and the gH\/gL\/pUL128\/130\/131 complex of human cytomegalovirus","volume":"65","author":"Su","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009169","article-title":"Rationally designed human cytomegalovirus gB nanoparticle vaccine with improved immunogenicity","volume":"16","author":"Perotti","year":"2020","journal-title":"PloS Pathog"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115646","article-title":"Structural basis of human cytomegalovirus neutralisation by gB AD-5-specific potent antibodies","volume":"44","author":"Wu","year":"2025","journal-title":"Cell Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36683-x","article-title":"The cytomegalovirus gB\/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread","volume":"14","author":"Gomes","year":"2023","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02393-14","article-title":"Identification of a neutralising epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus","volume":"89","author":"Wiegers","year":"2015","journal-title":"J Virol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/science.1126548","article-title":"Crystal structure of glycoprotein B from herpes simplex virus 1","volume":"313","author":"Heldwein","year":"2006","journal-title":"Science"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01045-2","article-title":"Development of a highly effective combination monoclonal antibody therapy against herpes simplex virus","volume":"31","author":"Seyfizadeh","year":"2024","journal-title":"J BioMed Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03200-13","article-title":"Mechanism of neutralisation of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B","volume":"88","author":"Cairns","year":"2014","journal-title":"J Virol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01700-10","article-title":"Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH\/gL, and gB","volume":"84","author":"Atanasiu","year":"2010","journal-title":"J Virol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralises dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920467","article-title":"Glycoprotein B antibodies completely neutralise EBV infection of B cells","volume":"13","author":"Hong","year":"2022","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein b of human cytomegalovirus which are target of neutralising antibodies","volume":"7","author":"P\u00f6tzsch","year":"2011","journal-title":"PloS Pathog"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00382-16","article-title":"In vitro characterisation of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539","volume":"60","author":"Patel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.3.533","article-title":"The humoral immune response against human cytomegalovirus is characterised by a delayed synthesis of glycoprotein-specific antibodies","volume":"175","author":"Schoppel","year":"1997","journal-title":"J Infect Dis"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralising antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"PNAS"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-8-2183","article-title":"Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralisation","volume":"80","author":"Speckner","year":"1999","journal-title":"J Gen Virol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1172\/jci161968","article-title":"A non-neutralising glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice","volume":"133","author":"Kuraoka","year":"2023","journal-title":"J Clin Invest"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285672","article-title":"A fully human neutralising monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B","volume":"18","author":"Roy","year":"2023","journal-title":"PloS One"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008961","article-title":"The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion","volume":"17","author":"Longnecker","year":"2021","journal-title":"PloS Pathog"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.04.043","article-title":"dbEBV: A database of Epstein-Barr virus variants and their correlations with human health","volume":"23","author":"Xie","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221797120","article-title":"Genomic and geographical structure of human cytomegalovirus","volume":"120","author":"Charles","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae283","article-title":"Viral genomic variation and the severity of genital herpes simplex virus-2 infection as quantified by shedding rate: a viral genome-wide association study","volume":"230","author":"Casto","year":"2024","journal-title":"J Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralising antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"PNAS"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.23.707514","article-title":"Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection","author":"Amlashi","year":"2026","journal-title":"bioRxiv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01924-10","article-title":"Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralisation of herpes simplex virus","volume":"85","author":"Krawczyk","year":"2011","journal-title":"J Virol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01821-25","article-title":"Enhanced rhLCV production in lymphoblastoid cell lines derived from rhLCV-infected cynomolgus macaque PBMCs","volume":"100","author":"Zhong","year":"2026","journal-title":"J Virol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202502231","article-title":"Structure and antigenicity of Kaposi\u2019s sarcoma\u2010associated herpesvirus glycoprotein B","volume":"12","author":"Fang","year":"2025","journal-title":"Adv Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10192-5","article-title":"A broadly protective antibody targeting gammaherpesvirus gB","volume":"653","author":"Sun","year":"2026","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/bf01323165","article-title":"HSV-1 gB and VZV gp-II crossreactive antibodies in human sera","volume":"112","author":"K\u00fchn","year":"1990","journal-title":"Arch Virol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013300","article-title":"Human herpesvirus 6B glycoprotein B postfusion structure, vulnerability mapping, and receptor recognition","volume":"21","author":"Heldwein","year":"2025","journal-title":"PloS Pathog"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlife.2023.12.004","article-title":"The structure of HSV-1 gB bound to a potent neutralising antibody reveals a conservative antigenic domain across herpesviruses","volume":"2","author":"Sun","year":"2024","journal-title":"hLife"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-79525-8.00034-2","article-title":"Protective capacity of neutralising and non-neutralising antibodies against glycoprotein B of cytomegalovirus","volume":"13","author":"Permar","year":"2017","journal-title":"PloS Pathog"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011670","article-title":"Protective mechanisms of nonneutralising antiviral antibodies","volume":"19","author":"Evans","year":"2023","journal-title":"PloS Pathog"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-05074-2","article-title":"Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon","volume":"81","author":"Mellors","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01450","article-title":"Viral evasion of the complement system and its importance for vaccines and therapeutics","volume":"11","author":"Mellors","year":"2020","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/v16071171","article-title":"The interactions of the complement system with human cytomegalovirus","volume":"16","author":"Lujan","year":"2024","journal-title":"Viruses"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralising antibody response","volume":"36","author":"Cui","year":"2018","journal-title":"Vaccine"},{"key":"B128","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41541-017-0038-0","article-title":"Complement enhances in vitro neutralising potency of antibodies to human cytomegalovirus glycoprotein B (Gb) and immune sera induced by Gb\/MF59 vaccination \/631\/250\/590\/2294 \/692\/53\/2423 article","volume":"2","author":"Li","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1986.tb04606.x","article-title":"Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralising antibodies via its expression in recombinant vaccinia virus","volume":"5","author":"Cranage","year":"1986","journal-title":"EMBO J"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.62.6.1881-1888.1988","article-title":"Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration","volume":"62","author":"Highlander","year":"1988","journal-title":"J Virol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralisation by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-40-2-443","article-title":"Complement-mediated cytolysis of HSV-1 and HSV-2 infected cells: Plasma membrane antigens reactive with type-specific and cross-reactive antibody","volume":"40","author":"Glorioso","year":"1978","journal-title":"J Gen Virol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.2.331","article-title":"Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralisation","volume":"162","author":"Harris","year":"1990","journal-title":"J Infect Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.34.2.336-346.1980","article-title":"Herpes simplex virus glycoproteins: Isolation of mutants resistant to immune cytolysis","volume":"34","author":"Machtiger","year":"1980","journal-title":"J Virol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05822-3","article-title":"EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma","volume":"22","author":"Zhu","year":"2024","journal-title":"J Transl Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02110","article-title":"The roles of host and viral antibody Fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity","volume":"10","author":"Jenks","year":"2019","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1128\/iai.37.3.1132-1137.1982","article-title":"Protection against lethal challenge of BALB\/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2","volume":"37","author":"Balachandran","year":"1982","journal-title":"Infect Immun"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1172\/jci114695","article-title":"Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B","volume":"86","author":"Kohl","year":"1990","journal-title":"J Clin Invest"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu8579","article-title":"Eliminating interactions with the viral Fc receptor improves antibody-mediated protection against neonatal HSV infection in mice","volume":"17","author":"Slein","year":"2025","journal-title":"Science Translational Medicine"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158206","article-title":"Analysis and fine specificity of the HCMV-specific cell-free and cell-associated antibody-dependent cellular phagocytosis (ADCP) responses in lung transplant recipients","volume":"22","author":"Eberhard","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1172\/jci156827","article-title":"Maternal Fc-mediated non-neutralising antibody responses correlate with protection against congenital human cytomegalovirus infection","volume":"132","author":"Semmes","year":"2022","journal-title":"J Clin Invest"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167768","article-title":"ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission","volume":"8","author":"Semmes","year":"2023","journal-title":"JCI Insight"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1172\/jci139296","article-title":"Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus","volume":"131","author":"Vlahava","year":"2021","journal-title":"J Clin Invest"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3611","article-title":"Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB\/MF59 vaccine in humans","volume":"12","author":"Jenks","year":"2020","journal-title":"Sci Transl Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0577-9","article-title":"Remodeling of host membranes during herpesvirus assembly and egress","volume":"10","author":"Lv","year":"2018","journal-title":"Protein Cell"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425622122","article-title":"Virion proteomics of genetically intact HCMV reveals a regulator of envelope glycoprotein composition that protects against humoral immunity","volume":"122","author":"Bentley","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"B147","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0147-9571(91)90123-u","article-title":"The glycoproteins of the human herpesviruses","volume":"14","author":"Manservigi","year":"1991","journal-title":"Comp Immunology Microbiol Infect Dis"},{"key":"B148","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0042-6822(92)90064-v","article-title":"Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion","volume":"186","author":"Navarro","year":"1992","journal-title":"Virology"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/v10090500","article-title":"Large-scale screening of HCMV-seropositive blood donors indicates that HCMV effectively escapes from antibodies by cell-associated spread","volume":"10","author":"Falk","year":"2018","journal-title":"Viruses"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410x(83)90008-7","article-title":"Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus","volume":"1","author":"Yamane","year":"1983","journal-title":"Vaccine"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-11-2867","article-title":"Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome","volume":"80","author":"Sinzger","year":"1999","journal-title":"J Gen Virol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.11.7586-7590.1994","article-title":"Analysis of the contributions of herpes simplex virus type 1 membrane proteins to the induction of cell-cell fusion","volume":"68","author":"Davis-Poynter","year":"1994","journal-title":"J Virol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.13050","article-title":"Establishment of a system to quantify wild\u2010type herpes simplex virus\u2013induced cell\u2013cell fusion reveals a role of N\u2010glycosylation of HSV\u20101 envelope glycoprotein B in cell\u2013cell fusion","volume":"67","author":"Fukui","year":"2023","journal-title":"Microbiol Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/v13040614","article-title":"Role of envelope glycoprotein complexes in cell-associated spread of human cytomegalovirus","volume":"13","author":"Weiler","year":"2021","journal-title":"Viruses"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1972","article-title":"Avoiding the void: cell-to-cell spread of human viruses","volume":"6","author":"Sattentau","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00070-19","article-title":"Cell-to-cell spread blocking activity is extremely limited in the sera of herpes simplex virus 1 (HSV-1)- and HSV-2-infected subjects","volume":"93","author":"Criscuolo","year":"2019","journal-title":"J Virol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.06.002","article-title":"Neutralising antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus","volume":"444","author":"Jacob","year":"2013","journal-title":"Virology"},{"key":"B158","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00430-010-0174-x","article-title":"Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity","volume":"200","author":"D\u00e4umer","year":"2010","journal-title":"Med Microbiol Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3390\/v14020284","article-title":"Neutralising antibodies limit cell-associated spread of human cytomegalovirus in epithelial cells and fibroblasts","volume":"14","author":"Reuter","year":"2022","journal-title":"Viruses"},{"key":"B160","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1099\/jgv.0.000605","article-title":"Epstein\u2013Barr virus exploits host endocytic machinery for cell-to-cell viral transmission rather than a virological synapse","volume":"97","author":"Nanbo","year":"2016","journal-title":"J Gen Virol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001338","article-title":"Epstein-Barr virus infection of polarised epithelial cells via the basolateral surface by memory B cell-mediated transfer infection","volume":"7","author":"Shannon-Lowe","year":"2011","journal-title":"PloS Pathog"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-025-02126-0","article-title":"Epstein\u2013Barr virus exploits desmocollin 2 as the principal epithelial cell entry receptor","volume":"10","author":"Wang","year":"2025","journal-title":"Nat Microbiol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.004","article-title":"Human inborn errors of immunity to herpes viruses","volume":"62","author":"Jouanguy","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03419-14","article-title":"Phenotypic and functional characterisation of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+T cells from symptomatic and asymptomatic individuals with ocular herpes","volume":"89","author":"Khan","year":"2015","journal-title":"J Virol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00692-08","article-title":"Asymptomatic human CD4+cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B","volume":"82","author":"Chentoufi","year":"2008","journal-title":"J Virol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003735","article-title":"Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL\/6 mice","volume":"186","author":"St. Leger","year":"2011","journal-title":"J Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.392","article-title":"Herpes simplex virus-specific CD8+ T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation","volume":"172","author":"van Lint","year":"2004","journal-title":"J Immunol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T\u2010cell\u2010inducing vaccines \u2013 what\u2019s the future","volume":"135","author":"Gilbert","year":"2011","journal-title":"Immunology"},{"key":"B169","year":""},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2564555","article-title":"Specificity and functional humoral immune responses induced by the VBI-1501A eVLP HCMV gB vaccine compared to the gB\/MF59 vaccine","volume":"21","author":"Connors","year":"2025","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B171","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilised prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.4.653","article-title":"Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection","volume":"161","author":"Mertz","year":"1990","journal-title":"J Infect Dis"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2022.12.003","article-title":"Novel monoclonal antibody-based therapies: Implications for the treatment and prevention of HCMV disease","volume":"31","author":"Nu\u00e9valos","year":"2023","journal-title":"Trends Microbiol"},{"key":"B174","author":"Stellbrink","year":""},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02467-19","article-title":"Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation","volume":"64","author":"Maertens","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01794-16","article-title":"Phase 2 randomised, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01108-17","article-title":"Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anticytomegalovirus monoclonal antibodies, in a phase 2a randomised trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients","volume":"62","author":"Deng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02178-24","article-title":"A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice","volume":"99","author":"Karthigeyan","year":"2025","journal-title":"J Virol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-025-02153-x","article-title":"Prefusion structure, evasion and neutralisation of HSV-1 glycoprotein B","volume":"10","author":"Roark","year":"2025","journal-title":"Nat Microbiol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","article-title":"A gB nanoparticle vaccine elicits a protective neutralising antibody response against EBV","volume":"31","author":"Sun","year":"2023","journal-title":"Cell Host Microbe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:07:56Z","timestamp":1780034876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1827628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":180,"alternative-id":["10.3389\/fimmu.2026.1827628"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1827628","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1827628"}}